PMID- 27780920
OWN - NLM
STAT- MEDLINE
DCOM- 20180222
LR  - 20220310
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 47
DP  - 2016 Nov 22
TI  - Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer.
PG  - 77793-77806
LID - 10.18632/oncotarget.12796 [doi]
AB  - Cellular adaptive mechanisms are crucial for tumorigenesis and a common feature 
      in solid tumor progression. Hypoxia-inducible factor-1alpha (HIF-1alpha) facilitates the 
      biological response to hypoxia, advancing angiogenesis and metastatic potential 
      of the tumor. The peroxisome proliferator-activated receptor gamma coactivators 1alpha 
      (PGC-1alpha) enhances mitochondrial biogenesis, favored by migratory/invasive cancer 
      cells. We conducted a prospective, long-term follow up study to determine whether 
      HIF-1alpha and PGC-1alpha can be implemented as predictive biomarker in breast cancer. 
      HIF-1alpha and PGC-1alpha plasma concentrations were measured in patients and in healthy 
      controls by enzyme linked immune sorbent assay. Breast cancer patients had 
      significantly higher HIF-1alpha and PGC-1alpha levels, which correlated with 
      clinicopathological features, overall with more aggressive cancer 
      characteristics. Disease free and overall survival of breast cancer patients with 
      high HIF-1alpha and PGC-1alpha were significantly poorer than in patients with low plasma 
      levels. In multivariate analysis, high amount of PGC-1alpha showed independent 
      prognostic value. Our data suggests that HIF-1alpha and PGC-1alpha may be promising, 
      noninvasive, biomarkers with a high potential for future clinical implication to 
      identify subgroups of patients with poorer prognosis and to indicate early, 
      subclinical metastasis.
FAU - Cai, Feng-Feng
AU  - Cai FF
AD  - Department of Breast Surgery, Yangpu Hospital, Tongji University School of 
      Medicine, Shanghai, PR China.
FAU - Xu, Cheng
AU  - Xu C
AD  - Department of Breast Surgery, Yangpu Hospital, Tongji University School of 
      Medicine, Shanghai, PR China.
FAU - Pan, Xin
AU  - Pan X
AD  - Department of Central Laboratory, Yangpu Hospital, Tongji University School of 
      Medicine, Shanghai, PR China.
FAU - Cai, Lu
AU  - Cai L
AD  - Department of Breast Surgery, Yangpu Hospital, Tongji University School of 
      Medicine, Shanghai, PR China.
FAU - Lin, Xiao-Yan
AU  - Lin XY
AD  - Department of Breast Surgery, Yangpu Hospital, Tongji University School of 
      Medicine, Shanghai, PR China.
FAU - Chen, Su
AU  - Chen S
AD  - Department of Molecular and Cellular Biology, School of Forensic Sciences, Xi'an 
      Jiao Tong University Health Science Center, Xi'an, Shaanxi, PR China.
FAU - Biskup, Ewelina
AU  - Biskup E
AD  - Department of Oncology, Department of Internal Medicine, University Hospital of 
      Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (PPARGC1A protein, human)
RN  - 0 (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/blood/*metabolism/*pathology
MH  - Female
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*blood
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/*blood
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Analysis
PMC - PMC5363621
OTO - NOTNLM
OT  - ELISA
OT  - HIF-1alpha
OT  - PGC-1alpha
OT  - breast cancer
OT  - prognosis
COIS- CONFLICTS OF INTEREST The authors have declared no conflicts of interest.
EDAT- 2016/10/27 06:00
MHDA- 2018/02/23 06:00
PMCR- 2016/11/22
CRDT- 2016/10/27 06:00
PHST- 2016/07/22 00:00 [received]
PHST- 2016/10/10 00:00 [accepted]
PHST- 2016/10/27 06:00 [pubmed]
PHST- 2018/02/23 06:00 [medline]
PHST- 2016/10/27 06:00 [entrez]
PHST- 2016/11/22 00:00 [pmc-release]
AID - 12796 [pii]
AID - 10.18632/oncotarget.12796 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Nov 22;7(47):77793-77806. doi: 10.18632/oncotarget.12796.